Generic Drug Price-Fixing End-Payer Settlements

Who Is Eligible?

You may be eligible to file a claim if you:

• The class covers anyone in the 50 states except Indiana and Ohio, plus the District of Columbia, Puerto Rico and the US Virgin Islands, who indirectly bought, paid for or reimbursed any of the Named Generic Drugs between 1 May 2009 and 31 December 2019, other than for resale.
• Indirectly is the operative word. You bought at a pharmacy counter rather than from the manufacturer, which is what makes you an end-payer rather than a direct purchaser.
• The drug has to be on the list. This is not every generic you have ever taken: the Named Generic Drugs are a defined set, published as a separate document on the settlement website, and the complaints name specific ones such as levothyroxine, doxycycline, pravastatin, propranolol, divalproex and digoxin. Check the list before assuming your prescription counts.
• Several groups are shut out, and one of them catches ordinary people. Consumers whose purchases were covered by Medicaid are excluded, as are all governmental Medicaid agencies and private Medicaid managed care organizations.
• Also excluded: the defendants and their officers, federal government entities, state government entities apart from cities, towns, counties and other local bodies with self-funded drug plans, judges on the case, anyone who bought only for resale or directly from a defendant, fully insured employers to the extent they use fully insured plans, and pharmacy benefit managers.
• Mixed purchases are handled sensibly. If some of what you bought qualifies and some falls inside an exclusion, you stay in the class for the qualifying purchases only.
• Your copay and your insurer's share are not the same claim. Where an insured consumer paid part of a drug's cost and a third-party payer paid the balance, the plan treats those as two separate non-duplicative claims.

How Much Can You Get?

No per-person figure has been published for any of these settlements, and the plan of allocation explains why one cannot be: your share depends on what everyone else claims.

Take the Sun/Taro fund as the worked example. It starts at $200 million. Up to $10 million of that can go back to Sun and Taro depending on how many class members opted out. From what remains the court may approve attorneys' fees of up to one third, notice and administration costs of up to $750,000, unreimbursed litigation expenses, a further $4 million set aside to fund the continuing case against the manufacturers who have not settled, and service awards of up to $500,000 for the class representatives.

What is left is the Net Settlement Fund, and it is divided pro rata. The administrator multiplies the net fund by your eligible purchases divided by the eligible purchases of every approved claimant. Spend more on the listed drugs across those ten years and you get a larger slice.

That formula is where consumer expectations usually break. Insurers and self-funded employer plans claim from the same pool on the same basis, and a decade of one plan's prescription spend runs to figures no household reaches.

There is no minimum payment yet. The plan asks the administrator to work out whether a minimum distribution would be economical at all, and class counsel would then have to ask the court to amend the plan to add one.

Nothing is paid until all four settlements have final approval, because the claims and distribution processes for Sun/Taro, Sandoz, Heritage and Apotex are being run together. Checks expire after about 90 days, and money left over can be redistributed to claimants who did cash them.

How to File Your Claim

File with the administrator:

• Check the drug list first. It is published on the settlement website as a separate document, and if none of your prescriptions appear on it there is nothing further to do.
• Then find your proofs of purchase. The consumer form asks for at least one for each drug you are claiming, plus the total you spent on that drug during the eligible period. Pharmacy printouts are the usual route: most chains will produce a prescription history for a patient on request, and that history is the document this claim turns on.
• File at genericdrugsendpayersettlement.com and choose the consumer form, not the third-party payer form. The second is for insurers and self-funded employer plans. You can also ring 1-877-316-0171 and ask for a paper form to be posted to you.
• Submit or postmark it by 9 November 2026.
• Do not pay anyone to do this for you. The administrator states on its own front page that class members need not sign up with a claims recovery firm or pay another firm to participate, and the court has gone further: after end-payer counsel moved for relief over misleading communications being sent to class members, it entered an order barring interference with the distribution.
• Sign it honestly. The form has to be executed with an affirmation that the information is true, and it warns that false statements can bring sanctions up to criminal prosecution.
• If something is missing you get a chance to fix it. Where the administrator needs more documentation it must write to you, explain the deficiency and give a reasonable deadline, and you can appeal a rejection to the court within 21 days.
• Opting out and objecting both closed long ago, on 2 December 2025. Filing or doing nothing are the remaining options, and doing nothing releases your claims against Sun and Taro anyway.

Frequently Asked Questions